The 1 analysts offering 12-month price forecasts for Progenics Pharmaceuticals Inc have a median target of 6.50, with a high estimate of 6.50 and a low estimate of 6.50. The median estimate represents a +52.58% increase from the last price of 4.26.
The current consensus among 1 polled investment analysts is to Buy stock in Progenics Pharmaceuticals Inc. This rating has held steady since February, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.24
Reporting Date Aug 06
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.